AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET

Company Participants

Tryn Stimart - Chief Legal and Compliance Officer
Carl Hansen - Chief Executive Officer
Andrew Booth - Chief Financial Officer

Conference Call Participants

Allison Bratzel - Piper Sandler
Andrea Tan - Goldman Sachs
Srikripa Devarakonda - Truist Securities
Evan Seigerman - BMO
David Martin - Bloom Burton
Brendan Smith - TD Securities

Operator

Good afternoon, and welcome to AbCellera’s Q3 2024 Business Update Conference Call. My name is Tamiya, and I will facilitate the audio portion of today's interactive broadcast. [Operator Instructions]

At this time, I would now like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. You may proceed.

Tryn Stimart

Thank you. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for joining us for AbCellera’s 2024 third quarter earnings call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Joining me on today's call are Dr. Carl Hansen, AbCellera's President and CEO; and Andrew Booth, AbCellera's Chief Financial Officer.

During this call, we anticipate making projections and forward-looking statements based on our current expectations and pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially due to several factors as set forth in our latest form 10-K and subsequent forms 10-Q and 8-K filed with the Securities and Exchange Commission. AbCellera does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Our presentation today including our earnings press release issued earlier today and our SEC filings are available on our Investor Relations website. The information we provide about our pipeline is for the benefit of the investment community and is not intended to be promotional. As we transition to our prepared remarks, please note that all dollars referred to during the call are in U.S. dollars. After our prepared remarks, we will open the lines for questions-and-answers.

Now, I'll turn the call over to Carl Hansen.

Carl Hansen

Thanks, Tryn, and thank you everyone for joining us today. Given that there were a few new disclosures this quarter, I'll use today's prepared remarks to give a brief update on AbCellera’s position and our progress. It was a year ago that we committed to building an internal pipeline and transitioning from a platform company to a clinical stage biotech. Over the past 12 months, we've reorganized our teams and reallocated our investments, focusing on advancing our internal programs and completing the build of our platform capabilities.